Positive regulation of Wee1 by Chk1 and 14-3-3 proteins

被引:220
|
作者
Lee, J [1 ]
Kumagai, A [1 ]
Dunphy, WG [1 ]
机构
[1] CALTECH, Howard Hughes Med Inst, Div Biol 216 76, Pasadena, CA 91125 USA
关键词
D O I
10.1091/mbc.12.3.551
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Wee1 inactivates the Cdc2-cyclin B complex during interphase by phosphorylating Cdc2 on Tyr-15. The activity of Wee1 is highly regulated during the cell cycle. In frog egg extracts, it has been established previously that Xenopus Wee1 (Xwee1) is present in a hypophosphorylated, active form during interphase and undergoes down-regulation by extensive phosphorylation at M-phase. We report that Xwee1 is also regulated by association with 14-3-3 proteins. Binding of 14-3-3 to Xwee1 occurs during interphase, but not M-phase, and requires phosphorylation of Xwee1 on Ser-549. A mutant of Xwee1 (S549A) that cannot bind 14-3-3 is substantially less active than wild-type Xwee1 in its ability to phosphorylate Cdc2. This mutation also affects the intranuclear distribution of Xwee1. In cell-free kinase assays, Xchk1 phosphorylates Xwee1 on Ser-549. The results of experiments in which Xwee1, Xchk1, or both were immunodepleted from Xenopus egg extracts suggested that these two enzymes are involved in a common pathway in the DNA replication checkpoint response. Replacement of endogenous Xwee1 with recombinant Xwee1-S549A in egg extracts attenuated the cell cycle delay induced by addition of excess recombinant Xchk1. Taken together, these results suggest that Xchk1 and 14-3-3 proteins act together as positive regulators of Xwee1.
引用
收藏
页码:551 / 563
页数:13
相关论文
共 50 条
  • [21] Chk1 and Wee1 kinases coordinate DNA replication, chromosome condensation, and anaphase entry
    Fasulo, Barbara
    Koyama, Carol
    Yu, Kristina R.
    Homola, Ellen M.
    Hsieh, Tao S.
    Campbell, Shelagh D.
    Sullivan, William
    MOLECULAR BIOLOGY OF THE CELL, 2012, 23 (06) : 1047 - 1057
  • [22] Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
    Chila, Rosaria
    Basana, Alessandra
    Lupi, Monica
    Guffanti, Federica
    Gaudio, Eugenio
    Rinaldi, Andrea
    Cascione, Luciano
    Restelli, Valentina
    Tarantelli, Chiara
    Bertoni, Francesco
    Damia, Giovanna
    Carrassa, Laura
    ONCOTARGET, 2015, 6 (05) : 3394 - 3408
  • [23] ATR/CHK1/WEE1 DEPENDENCY IN SRSF2-MUTATED MDS/AML
    Eldfors, Samuli
    Rai, Sumit
    Sharma, Vineet
    Hossan, Tareq
    Cabrera, Claudia
    Bertino, Amy
    Gilbert, Angelique
    Walter, Matthew
    Porkka, Kimmo
    Graubert, Timothy
    EXPERIMENTAL HEMATOLOGY, 2024, 137
  • [24] Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma
    Russell, Mike R.
    Levin, Kirill
    Rader, JulieAnn
    Belcastro, Lili
    Li, Yimei
    Martinez, Daniel
    Pawel, Bruce
    Shumway, Stuart D.
    Maris, John M.
    Cole, Kristina A.
    CANCER RESEARCH, 2013, 73 (02) : 776 - 784
  • [25] Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells
    Mak, Joyce P. Y.
    Man, Wing Yu
    Chow, Jeremy P. H.
    Ma, Hoi Tang
    Poon, Randy Y. C.
    ONCOTARGET, 2015, 6 (25) : 21074 - 21084
  • [26] Chk1 and 14-3-3 proteins inhibit atypical E2Fs to prevent a permanent cell cycle arrest
    Yuan, Ruixue
    Vos, Harmjan R.
    van Es, Robert M.
    Chen, Jing
    Burgering, Boudewijn M. T.
    Westendorp, Bart
    de Bruin, Alain
    EMBO JOURNAL, 2018, 37 (05):
  • [27] Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine
    Koh, Siang-Boon
    Wallez, Yann
    Dunlop, Charles R.
    Fernandez, Sandra Bernaldo de Quiros
    Bapiro, Tashinga E.
    Richards, Frances M.
    Jodrell, Duncan I.
    CANCER RESEARCH, 2018, 78 (11) : 3054 - 3066
  • [28] EVALUATION OF BBB PERMEABLE WEE1 AND CHK1 INHIBITORS IN COMBINATION WITH STANDARD OF CARE FOR THE TREATMENT OF GLIOBLASTOMA
    Scholefield, E. L.
    Gomez-Roman, N.
    NEURO-ONCOLOGY, 2024, 26 : V72 - V72
  • [29] NEW INSIGHTS INTO MK 1775 RESISTANCE: DUAL INHIBITION OF WEE1 AND CHK1 IN UGC TREATMENT
    Thangaretnam, K.
    Islam, M. O.
    Lu, H.
    Peng, D.
    Bhat, N.
    Soutto, M.
    El-Rifai, Wael
    Chen, Z.
    GASTROENTEROLOGY, 2024, 166 (05) : S689 - S689
  • [30] A siRNA high-throughput screening identified Wee1 as determinant of Chk1 inhibitor sensitivity
    Carrassa, Laura
    Chila, Rosaria
    Lupi, Monica
    Ricci, Francesca
    Mazzoletti, Marco
    Celenza, Cinzia
    Broggini, Massimo
    Damia, Giovanna
    CANCER RESEARCH, 2012, 72